Utilisation of the ESMO-MCBS in practice of HTA

Wild, C. and Grössmann, N. and Bonanno, P. V. and Bucsics, A. and Furst, J. and Garuoliene, K. and Godman, B. and Gulbinovič, J. and Jones, J. and Pomorski, M. K. and Emprechtinger, R. (2016) Utilisation of the ESMO-MCBS in practice of HTA. Annals of Oncology, 27 (11). pp. 2134-2136. ISSN 1569-8041

[thumbnail of Wild-AOO-2016-Utilisation-of-the-ESMO-MCBS-in-practice]
Text (Wild-AOO-2016-Utilisation-of-the-ESMO-MCBS-in-practice)
Accepted Author Manuscript

Download (615kB)| Preview


    It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.